Subscribe to our Newsletter

Stay up to date with the latest thought leadership articles and news from CordenPharma.

Catalogue of Products

Product Lists

White Papers

Battling Counterfeit Medicine Through Packaging Serialization >> Download Here

By Mario Scigliano, Global Serialization Manager, CordenPharma Latina & Christian Ahlmark, Associate Director, Sales & Key Account Management, CordenPharma International

Get informed about packaging serialization regulatory requirements & deadlines for global markets in this CordenPharma white paper discussing keys to combating the worldwide drug counterfeiting problem. Topics include serialization techniques in the supply chain such as Microscopic RFID Tags, Security Labels, Invisible Inks, and Track-and-Trace Technologies. Learn the importance and benefits of choosing the right CDMO to ensure the utmost level of support in keeping patients safe.

Minimizing Risk In API & Drug Product Development & Manufacturing: A Fully Integrated Supply Chain >> Download Here

C&EN White Paper brought to you by CordenPharma

The pharmaceutical and biopharma industry continues to experience solid growth in an expanding global market. This market growth has been accompanied by an ever-changing industry landscape, with consolidation among long-time “big pharma” leaders, ongoing mergers and acquisitions, and the emergence of start-ups and technology-based offshoots from academic laboratories. As the industry continuously adapts to evolving market pressures, the trend toward outsourcing of APIs & Drug Products to CDMOs with specialized capabilities, expertise and infrastructure remains a strong one.

Videos & Podcasts

Podcast: Manufacturing APIs with Asian Supply Chains, by Dr. Stephen Houldsworth >> Listen to Podcast

May 31, 2019

Dr. Stephen Houldsworth, Director, Global Small Molecules & Antibiotics Platforms, talks with Pharmaceutical Technology's Managing Editor of Special Projects about CordenPharma's response to recent news regarding Sartan drugs with carcinogenic impurities that were tracked back to various Asian sources, including the various concerns that the Pharma Industry needs to take into consideration and how price factors into these decisions.

Glatt @ CordenPharma Plankstadt >> Watch Video

April 20, 2018

View this video taken at CordenPharma Plankstadt highlighting Glatt's leading technology for highly potent laboratory scale containment pharma solutions. CordenPharma Plankstadt (DE) trusts in Glatt Technology. In technological partnership with Weiss Pharmatechnik, Glatt provides state-of-the-art pharma process solutions combined with top flexible barrier systems for highly potent containment developing services up to OEB 5 Level.

CordenPharma Plankstadt Expanded Highly Potent Development Facility >> Watch Video

Mar 30, 2016

On March 14, 2016, CordenPharma was pleased to announce the completion and approval of expanded Development Capabilities (CTD2) for mid-scale (up to 20 kg) contained capacity of highly potent and oncology oral dosage forms in CordenPharma Plankstadt (DE). This new and expanded capability provides customers a complete offering in the contained manufacturing of oral dosage from grams to 150 Kg.


Navigating Injectable Combination Device & Drug Product Regulations: How a Full-Service CDMO Supports Pharma >> View Webinar On Demand

By Fabio Stevanon, Director, Global Injectables Platform, CordenPharma International

& Mark Chipperfield, Principal Consultant & Company Director, Corvus Device Ltd.

This webinar, given live on September 12, 2019, discusses:

  • >> Understand what IS / what IS NOT a combination device-drug product.
  • >> Gain insight into the major regulation landscape for combined drug & device products, including some technical challenges for injectable PreFilled Syringes (PFS) & Auto-injectors.
  • >> Get an overview of how a sound injectable drug product strategy by a Full-Service CDMO helps navigate industry changes to support your drug development goals.
  • >> Learn ways of partnering with a global CDMO to efficiently commercialize an injectable drug, with specific recommendations on finding solutions for injectable combination device-drug product challenges.

Critical Aspects of a Robust Highly Potent Compound Program: The Importance of Understanding Intangible Elements of Containment >> View Webinar On Demand

By Robin Livingston, Environmental, Health & Safety Manager, CordenPharma Colorado

This webinar, given live on April 4, 2018, discusses:

  • >> Learn the importance of understanding intangible soft elements of a robust potent compound program.
  • >> Hear a detailed explanation of each aspect of a strong highly potent compound program.
  • >> Plan for an on-going robust containment system, long after installation.
  • >> Learn practical ways to apply these elements to your company’s potent compound program.

Implementing a Quality by Design Development Philosophy: Benefits & Challenges in a Highly Potent Landscape >> View Webinar On Demand

By Dr. Iris Ziegler, Director, Pharmaceutical Sciences & QbD, CordenPharma International

This webinar, given live on October 4, 2017, discusses:

  • >> Quality by Design (QbD) - where are we in Pharma after almost 10 years post ICHQ8?
  • >> Can a CDMO afford QbD and what if the customer does not want it?
  • >> What are the real benefits of a QbD mind-set in a Highly Potent manufacturing environment?
  • >> Examine at a case study on applying the QbD approach to the development of a Highly Potent Drug Product

From Market Compliance to Business Supply: The Necessity for Serialization >> View Webinar On Demand

By Mario Scigliano, Global Serialization Manager, CordenPharma Latina

This webinar, given live on March 8, 2017, discusses:

  • >> How various markets approach specific necessities and technical difficulties
  • >> The design of appropriate IT infrastructure
  • >> How communication across the track and trace concept is applied to the supply chain
  • >> The major initiatives in the installation, integration and implementation of serialization and aggregation from unit carton to pallet
  • >> Serialization requirements in China, South Korea, Saudi Arabia, US, and Europe

Speaking Presentations

Tides 2019, San Diego, CA (US)

May 20, 2019 >> Peptide CMC Approaches for a Fast & Successful IND Filing

by Dr. Mimoun Ayoub, Director, Head of North America & Emerging Market Sales, CordenPharma International

Tides 2019, San Diego, CA (US)

May 22, 2019 >> Peptide Manufacturing Scale-up Considerations

by Dr. Robert Topping, Distinguished Scientist, Development Synthetic Chemistry, CordenPharma Colorado

Tides 2019, San Diego, CA (US)

May 23, 2019 >> Aggregation of Peptides in Preparative Chromatography

by Anthony Zidell, Analytical Chemist, CordenPharma Colorado

CPhI Japan 2019, Tokyo, Japan

March 18, 2019 >> Fully Integrated Peptide Drug Substance and Drug Product Manufacturing

by Dr. Frieder Mitzel, Associate Director, Sales & Key Account Management, CPI

Tides 2018, Boston, MA (US)

May 9, 2018 >> Producing the Highly Potent Peptide

by Dr. Richard Dauer, Distinguished Engineer, CordenPharma Colorado

Pharma Congress 2018, Düsseldorf, Germany

April 24, 2018 >> Keynote Speech: Continuous Manufacturing – A Case Study

by Yves Michon, Managing Director, CordenPharma Chenôve (FR)

CPhI Japan 2018, Tokyo, Japan

April 18, 2018 >> Development & Manufacturing of Peptides

by Dr. Frieder Mitzel, Associate Director, Sales & Key Account Management, CPI